The vaccinia virus fusion inhibitor proteins SPI-3 (K2) and HA (A56) expressed by infected cells reduce the entry of superinfecting virus

Virology

Volumn 380, Issue 2, 2008, Pages 226-233

  Turner, Peter C ^a   Moyer, Richard W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cell cell fusion; Hemagglutinin (A56R); Luciferase; Orthopoxvirus; SPI 3 (K2L); Superinfection; Vaccinia virus; Virus entry

Indexed keywords

HEMAGGLUTININ; LUCIFERASE; SERINE PROTEINASE INHIBITOR;

ARTICLE; CELL FUSION; CELL SURFACE; CONTROLLED STUDY; COWPOX VIRUS; ENZYME ACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; VACCINIA VIRUS; VIRUS CELL INTERACTION;

ANIMALS; CERCOPITHECUS AETHIOPS; LUCIFERASES; STAINING AND LABELING; VACCINIA VIRUS; VERO CELLS; VIRAL PROTEINS; VIRUS ATTACHMENT; VIRUS INTERNALIZATION;

COWPOX VIRUS; ORTHOPOXVIRUS; VACCINIA VIRUS;

EID: 53249113139     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.07.020     Document Type: Article

References (36)

1. Brown E., Senkevich T.G., and Moss B. Vaccinia virus F9 virion membrane protein is required for entry but not virus assembly, in contrast to the related L1 protein. J. Virol. 80 (2006) 9455-9464
2. Brum L.M., Turner P.C., Devick H., Baquero M.T., and Moyer R.W. Plasma membrane localization and fusion inhibitory activity of the cowpox virus serpin SPI-3 require a functional signal sequence and the virus encoded hemagglutinin. Virology 306 (2003) 289-302
3. Buchholz U.J., Finke S., and Conzelmann K.K. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73 (1999) 251-259
4. Chakrabarti S., Sisler J.R., and Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. BioTechniques 23 (1997) 1094-1097
5. Christen L., Seto J., and Niles E.G. Superinfection exclusion of vaccinia virus in virus-infected cell cultures. Virology 174 (1990) 35-42
6. Condit R.C., Moussatche N., and Traktman P. In a nutshell: structure and assembly of the vaccinia virion. Adv. Virus Res. 66 (2006) 31-124
7. Fuerst T.R., Niles E.G., Studier F.W., and Moss B. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 8122-8126
8. Ichihashi Y., and Dales S. Biogenesis of poxviruses: interrelationship between hemagglutinin production and polykaryocytosis. Virology 46 (1971) 533-543
9. Izmailyan R.A., Huang C.Y., Mohammad S., Isaacs S.N., and Chang W. The envelope G3L protein is essential for entry of vaccinia virus into host cells. J. Virol. 80 (2006) 8402-8410
10. Johnson R.M., and Spear P.G. Herpes simplex virus glycoprotein D mediates interference with herpes simplex virus infection. J. Virol. 63 (1989) 819-827
11. Katsafanas G.C., and Moss B. Colocalization of transcription and translation within cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions. Cell Host. Microbe 2 (2007) 221-228
12. Law K.M., and Smith G.L. A vaccinia serine protease inhibitor which prevents virus-induced cell fusion. J. Gen.Virol. 73 (1992) 549-557
13. Law M., Carter G.C., Roberts K.L., Hollinshead M., and Smith G.L. Ligand-induced and nonfusogenic dissolution of a viral membrane. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5989-5994
14. Moss B. Poxviridae: the viruses and their replication. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Virology (2001), Raven Press, New York 2849-2883
15. Moss B. Poxvirus entry and membrane fusion. Virology 344 (2006) 48-54
16. Moss B., Elroy Stein O., Mizukami T., Alexander W.A., and Fuerst T.R. Product review. New mammalian expression vectors. Nature 348 (1990) 91-92
17. Ojeda S., Domi A., and Moss B. Vaccinia virus G9 protein is an essential component of the poxvirus entry-fusion complex. J. Virol. 80 (2006) 9822-9830
18. Ojeda S., Senkevich T.G., and Moss B. Entry of vaccinia virus and cell-cell fusion require a highly conserved cysteine-rich membrane protein encoded by the A16L gene. J. Virol. 80 (2006) 51-61
19. Palese P., Tobita K., Ueda M., and Compans R.W. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61 (1974) 397-410
20. Payne L.G. Identification of the vaccinia hemagglutinin polypeptide from a cell system yielding large amounts of extracellular enveloped virus. J. Virol. 31 (1979) 147-155
21. Payne L.G. Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J. Gen. Virol. 50 (1980) 89-100
22. Senkevich T.G., and Moss B. Vaccinia virus H2 protein is an essential component of a complex involved in virus entry and cell-cell fusion. J. Virol. 79 (2005) 4744-4754
23. Senkevich T.G., Ward B.M., and Moss B. Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene. J. Virol. 78 (2004) 2357-2366
24. Senkevich T.G., Ojeda S., Townsley A., Nelson G.E., and Moss B. Poxvirus multiprotein entry-fusion complex. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18572-18577
25. Smith G.L., Vanderplasschen A., and Law M. The formation and function of extracellular enveloped vaccinia virus. J. Gen.Virol. 83 (2002) 2915-2931
26. Townsley A.C., and Moss B. Two distinct low-pH steps promote entry of vaccinia virus. J. Virol. 81 (2007) 8613-8620
27. Townsley A.C., Senkevich T.G., and Moss B. The product of the vaccinia virus L5R gene is a fourth membrane protein encoded by all poxviruses that is required for cell entry and cell-cell fusion. J. Virol. 79 (2005) 10988-10998
28. Townsley A.C., Senkevich T.G., and Moss B. Vaccinia virus A21 virion membrane protein is required for cell entry and fusion. J. Virol. 79 (2005) 9458-9469
29. Townsley A.C., Weisberg A.S., Wagenaar T.R., and Moss B. Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway. J. Virol. 80 (2006) 8899-8908
30. Turner P.C., and Moyer R.W. An orthopoxvirus serpinlike gene controls the ability of infected cells to fuse. J. Virol. 66 (1992) 2076-2085
31. Turner P.C., and Moyer R.W. Orthopoxvirus fusion inhibitor glycoprotein SPI-3 (open reading frame K2L) contains motifs characteristic of serine proteinase inhibitors that are not required for control of cell fusion. J. Virol. 69 (1995) 5978-5987
32. Turner P.C., and Moyer R.W. The cowpox virus fusion regulator proteins SPI-3 and hemagglutinin interact in infected and uninfected cells. Virology 347 (2006) 88-99
33. Turner P.C., Baquero M.T., Yuan S., Thoennes S.R., and Moyer R.W. The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin. Virology 272 (2000) 267-280
34. Wagenaar T.R., and Moss B. Association of vaccinia virus fusion regulatory proteins with the multicomponent entry/fusion complex. J. Virol. 81 (2007) 6286-6293
35. Whitaker-Dowling P., Youngner J.S., Widnell C.C., and Wilcox D.K. Superinfection exclusion by vesicular stomatitis virus. Virology 131 (1983) 137-143
36. Zhou J., Sun X.Y., Fernando G.J., and Frazer I.H. The vaccinia virus K2L gene encodes a serine protease inhibitor which inhibits cell-cell fusion. Virology 189 (1992) 678-686